Please accept our sympathy.My Husband had three treatments of Chemo therapy for colon cancer but could not tolorate it, then swiched to Xeloda. Myths or unrealistic expectations tied to switching medications should be empathically ascertained and clarified. In the past, he has served on Speaker Bureaus for Janssen Pharmaceutica and Pfizer, Inc.Ralph Aquila, MD, (peer/content reviewer) has disclosed that he participates in speaker bureau programs for Novartis, Sunovion, Lilly, and he serves as a consultant for Novartis. Mostly I dont have side effects but noticed that my weight is on the increased, 10 pounds in the last month. Fight Colorectal Cancer has a I had 2 5-FU treatments, the first treatment caused a heart attack, the second caused severe chest pains but had nitro so it wouldn’t turn into another heart attack (though while in the hospital on a monitor my heart stopped) they figured out it was vessel spasms & was taken off 5-FU & they gave me a month to recuperate before putting me on Xeloda. This category only includes cookies that ensures basic functionalities and security features of the website. Select whether the change is from an oral to another oral formulation, or from a depot to another depot formulation. )However, the trial was halted after 40 of a planned 74 patients were enrolled because of the high toxicity in the first group who made the 5-FU to Xeloda switch.
They should discuss such switches carefully with their oncologists.Because folate in cells may be the reason for increased serious side effects, patients should discuss all sources of supplementary folic acid with their doctors, including that in enriched foods and multivitamins.The National Institutes of Health Office of Dietary Supplements has hi, my father suffering from gastric cancer( signet ring type) for 1.5 yrs . However, we at C3 are not physicians and cannot know if a particular drug might have caused a serious side effect for a particular patient.Your own doctor is the best person to ask about the situation. he hadnt any surgery for this problem and have been treated with xeloda but because of spread of cancer to adjacent lymph nodes his oncologist switched xeloda to 5fu . An immediate switch from 5-FU treatment to Xeloda® (capecitabine) for stage III colon cancer caused so much toxicity that a Patients in the Patient Preference in Adjuvant Therapy (PACT) trial who switched after 6 weeks from weekly 5-FU with leucovorin to oral capecitabine experienced excessive side effects. The second group began with Xeloda during the start period and got 5-FU during the switch period. after that he became ill and because of diarrhea and anorexia he isnt well . If there is an option to switch to Xeloda, is this the best option for adjuvant therapy (stage 3c) in view of the increased side effect of switching from 5FU to capecitabine? Obviously, I’ll send this study to my oncologist and discuss with her. This may be especially so when:• Clinical factors associated with poor response to treatment have been ruled out (eg, misdiagnosis, comorbidities, poor medication adherence, inadequate dosage or duration of treatment)• Optimization of antipsychotic dose and/or taking a medication for a long time has not resulted in added benefit• Further dose increases or combination pharmacotherapy is contraindicated, is not likely to be effective, or is otherwise not feasible• A patient acutely relapses despite good medication adherenceThus, before making the decision to switch, great care must be taken to ensure that treatment with the pre-switch antipsychotic was optimized in terms of adherence, treatment duration, and dose.• The antipsychotic dose cannot be lowered because of unacceptable risk of clinical worsening• A treatment-limiting adverse effect is unlikely to diminish at lower doses• Specific treatments (such as an anticholinergic medication for managing antipsychotic-induced extrapyramidal effects) for a treatment-limiting adverse effect do not exist, are ineffective, or are contraindicated• Antipsychotic treatment has resulted in clinically significant increases in glucose or lipid levels, and the patient is unwilling or incapable of adhering to dietary or medical interventions (or dietary or medical intervention is ineffective)When intolerable adverse effects occur as a result of drug-drug interactions, it is often necessary to reduce the dosage of-or discontinue altogether-the complicating medication.